What is central neurocytoma?
Central neurocytoma is an uncommon brain tumour that grows inside the fluid-filled spaces of the brain, called the ventricles. It almost always starts in one of the two lateral ventricles, close to a small opening called the foramen of Monro and the thin wall that divides the ventricles, the septum pellucidum.
The tumour is made of small, rounded cells that resemble immature nerve cells (neurons). This is what the word “neurocytoma” refers to.
Central neurocytoma is classed by the World Health Organization as a CNS WHO grade 2 tumour. It usually grows slowly and rarely spreads, but it can still cause serious problems because it blocks the flow of cerebrospinal fluid. This leads to a build-up of fluid and pressure in the head, known as hydrocephalus.
It mainly affects young adults in their 20s and 30s. With modern surgery, and radiotherapy or radiosurgery when needed, most people live long lives after treatment (Lee et al., 2016).
1. Key facts at a glance
| Feature | Details |
|---|---|
| Type of tumour | Neuronal tumour of the ventricles |
| WHO grade | CNS WHO grade 2 |
| How common | Rare; well under 1% of all brain tumours |
| Typical age | Young adults; most between 20 and 40, average about 30 |
| Sex | Men and women affected about equally |
| Usual site | Lateral ventricle near the foramen of Monro; sometimes the third ventricle |
| Main problem | Blocked fluid flow causing hydrocephalus |
| Main treatment | Surgical removal; radiotherapy or radiosurgery for leftover or recurrent tumour |
| Outlook | Very good; long-term survival above 90% in most series |
2. Causes and risk factors
The cause of central neurocytoma is not known. It is not linked to head injury, mobile phones, diet or lifestyle. It is not inherited and does not usually run in families.
| Factor | Notes |
|---|---|
| Age | Mostly young adults; children and older adults are affected less often |
| Radiation to the head | A known risk factor for brain tumours in general, but rarely relevant here |
| Genetic syndromes | No clear link has been found |
Research suggests the tumour starts from immature cells near the ventricle walls that can develop into nerve cells. Specific repeated gene changes, like those in many other brain tumours, have not been identified, although these tumours share a typical DNA methylation profile.
3. How does it look
On scans
| Feature | Description |
|---|---|
| Position | Inside the lateral ventricle, attached to the septum pellucidum or ventricle wall |
| Shape | A rounded, lobulated mass with a “bubbly” or soap-bubble look from small cysts |
| Calcification | Common; seen best on CT |
| MRI signal | Mixed signal with patchy enhancement after contrast |
| Blood vessels | Small flow voids may be visible |
| Ventricles | Often enlarged on one or both sides because fluid cannot drain |
| Size | Often 3-6 cm at diagnosis |
During surgery
The tumour is usually grey or reddish, soft and moderately rich in blood vessels. It is often well defined, which helps surgeons remove it, but it can be firmly stuck to the ventricle wall or to deep veins.
Under the microscope
| Feature | Description |
|---|---|
| Cells | Uniform small round cells with round nuclei and fine “salt and pepper” chromatin |
| Halo | Clear space around the nucleus, similar to oligodendroglioma |
| Pattern | Sheets of cells with fibrillary islands and thin blood vessels |
| Neuronal markers | Synaptophysin and NeuN positive |
| Proliferation | Ki-67 usually low; above about 2-3% suggests “atypical” neurocytoma with higher recurrence risk |
| Electron microscopy | Shows tiny vesicles and nerve-like processes (rarely needed today) |
Similar tumours
| Tumour | How it differs |
|---|---|
| Oligodendroglioma | Grows in brain tissue, not the ventricle; has IDH mutation and 1p/19q codeletion |
| Ependymoma | Different markers and growth pattern |
| Subependymoma | Benign, often found by chance in older adults |
| Extraventricular neurocytoma | Similar cells but grows in brain tissue outside the ventricles |
4. Symptoms
Most symptoms come from raised pressure inside the head because the tumour blocks fluid drainage. They often build up over weeks to months, but can worsen suddenly.
Common symptoms
- Headache, often worse in the morning or when lying down
- Nausea and vomiting
- Blurred or double vision
- Drowsiness or unusual tiredness
- Memory problems and difficulty concentrating
- Unsteadiness when walking
Less common symptoms
| Symptom | Notes |
|---|---|
| Seizures | Uncommon, because the tumour lies in the ventricle rather than brain tissue |
| Changes in mood or personality | From pressure on nearby brain regions |
| Hormone or sleep changes | If the tumour presses on the hypothalamus |
| Sudden severe headache or collapse | Bleeding into the tumour or sudden blockage; a medical emergency |
Signs a doctor may find
| Sign | Meaning |
|---|---|
| Papilloedema | Swelling of the optic disc at the back of the eye, a sign of raised pressure |
| Problems with eye movements | Pressure on nerves controlling the eyes |
| Poor balance | Effects of hydrocephalus |
When to seek medical advice
See a doctor promptly about new, persistent or worsening headaches, especially with vomiting, blurred vision or confusion. Seek emergency care for a sudden, severe headache, repeated vomiting, a seizure or loss of consciousness.
Central neurocytoma in children
Central neurocytoma is uncommon in children and teenagers, but it does occur. Reviews of children with this tumour describe the same features as in adults: a mass in the lateral ventricle, hydrocephalus and a good outlook after removal. Some reports suggest that tumours in young people may more often show atypical features, so careful follow-up is important (Karthigeyan, Gupta and Salunke, 2017).
5. Diagnosis
| Test | Purpose |
|---|---|
| Neurological examination | Checks vision, balance, strength and thinking |
| Eye examination | Looks for papilloedema |
| CT scan | Quickly shows the mass, hydrocephalus and calcification |
| MRI with contrast | Main test; shows the tumour in detail and plans surgery |
| MR spectroscopy | May show a pattern typical of neuronal tumours |
| Spine MRI | Sometimes done to exclude spread, which is rare |
| Surgery and pathology | Confirms the diagnosis and measures Ki-67 |
6. Treatment
Treatment is planned by a neuro-oncology team of neurosurgeons, neuro-oncologists, radiation oncologists and specialist nurses.
Relieving pressure
If there is severe hydrocephalus, an external ventricular drain may be placed before or during surgery. Some people need a permanent shunt after the tumour is removed if fluid still does not drain normally (Soliman, 2017).
Surgery
| Approach | Notes |
|---|---|
| Transcallosal approach | Through the gap between the two halves of the brain and the corpus callosum |
| Transcortical approach | Through a small opening in the brain surface into an enlarged ventricle |
| Endoscopic surgery | For biopsy, smaller tumours or to restore fluid flow |
| Gross total resection | The main goal; offers the best long-term control |
Complete removal is often curative. When part of the tumour must be left, for example because it is attached to deep veins, further treatment may be offered.
Radiotherapy and radiosurgery
| Option | When it is used |
|---|---|
| Stereotactic radiosurgery (such as Gamma Knife) | Small residual or recurrent tumour; high local control rates in pooled studies (Spina et al., 2024) |
| Fractionated radiotherapy | Larger residual tumour or atypical neurocytoma |
| Watch and wait with MRI | Small residual tumour with low Ki-67 |
Chemotherapy
Chemotherapy is rarely used. It may be considered for the uncommon tumour that keeps growing despite surgery and radiotherapy.
Side effects and risks
| Treatment | Possible effects |
|---|---|
| Surgery | Short-term memory problems, bleeding, seizures, infection, temporary weakness |
| Shunt | Blockage or infection needing further surgery |
| Radiosurgery | Swelling near the treated area, headache |
| Fractionated radiotherapy | Tiredness, hair loss in the treated area, later effects on memory |
What treatment involves day to day
| Part of treatment | What to expect |
|---|---|
| Brain surgery | A general anaesthetic; often 1-2 days in intensive or high-dependency care |
| Hospital stay | Usually about 5-10 days |
| Recovery at home | Several weeks of rest; tiredness is common |
| Radiosurgery | Usually a single outpatient session lasting a few hours |
| Fractionated radiotherapy | Short daily sessions on weekdays for about 5-6 weeks |
Recovery after surgery
Many people feel tired and slow for some weeks after surgery. Short-term memory problems are common at first, because the route to the ventricles passes close to structures involved in memory. These usually improve over months. Rehabilitation from occupational therapists, physiotherapists and neuropsychologists can help with daily activities, concentration and returning to work or study.
7. Outlook (prognosis)
| Situation | Approximate outlook |
|---|---|
| Complete removal | Long-term control in about 9 in 10 people; survival at 5 years over 95% |
| Partial removal without further treatment | Higher chance of regrowth |
| Partial removal plus radiotherapy or radiosurgery | Control rates approaching those after complete removal |
| Atypical neurocytoma (high Ki-67) | More likely to recur; close follow-up needed |
Figures come from reviews of published series (Schmidt et al., 2004; Lee et al., 2016). Even when the tumour comes back, it can often be treated again successfully. Spread through the spinal fluid is rare.
Who is at risk of the tumour coming back?
| Factor | Effect on risk of regrowth |
|---|---|
| Partial removal | The strongest risk factor |
| High Ki-67 (atypical neurocytoma) | Higher risk, especially above about 2-3% |
| Large tumour or attachment to deep veins | Makes complete removal harder |
| Unusual features under the microscope | Such as necrosis or many dividing cells |
In one study that followed people for about 8 years on average after Gamma Knife radiosurgery, the tumour stayed under control in roughly 9 in 10 at 5 years and just over 8 in 10 at 10 years. When radiosurgery was used for tumour left behind after an operation, several of the failures happened just outside the treated zone. For this reason, follow-up scans look at the whole ventricular system, not only the treated spot (Kim et al., 2013).
8. Follow-up
| Follow-up | Purpose |
|---|---|
| MRI 3 months after surgery | Shows how much tumour remains |
| MRI every 6-12 months for several years | Detects regrowth early |
| Neuropsychology review | Assesses memory and concentration |
| Shunt checks | If a shunt was fitted |
| Eye checks | If vision was affected |
9. Living with central neurocytoma
- Allow time to recover; tiredness and memory problems can last several months after surgery
- Use memory aids such as notebooks, phone reminders and calendars
- Ask about driving rules, which may apply after brain surgery or seizures; your licensing authority can explain what applies to you
- Learn the warning signs of shunt problems, such as returning headache, vomiting or drowsiness
- Plan a gradual return to work or study, with adjustments if needed
- Seek support from brain tumour charities and patient groups
10. Frequently asked questions
| Question | Answer |
|---|---|
| Is central neurocytoma cancer? | It is a tumour with low-grade, usually slow behaviour; it rarely spreads |
| Is it inherited? | No |
| Will I need a shunt for life? | Many people do not; some need one if fluid still fails to drain |
| Can it come back? | Yes, especially after partial removal or when Ki-67 is high |
| Will I need chemotherapy? | Very rarely |
| Can I have children? | Usually yes; the tumour and its usual treatments do not affect fertility directly |
11. Questions to ask your care team
- Was the tumour completely removed?
- What was the Ki-67 index, and is it an atypical neurocytoma?
- Do I need radiotherapy, radiosurgery or just scans?
- Will I need a shunt, and what are the warning signs of a problem?
- How might surgery affect my memory or concentration?
- When can I drive, work or exercise again?
Resources
- Bui, T.T. et al. (2017) ‘Systematic analysis of clinical outcomes following stereotactic radiosurgery for central neurocytoma’, Brain Tumor Research and Treatment, 5(1), pp. 10-15.
- Karthigeyan, M., Gupta, K. and Salunke, P. (2017) ‘Pediatric central neurocytoma’, Journal of Child Neurology, 32(1), pp. 53-59.
- Kim, J.W. et al. (2013) ‘Radiosurgery for central neurocytoma: long-term outcome and failure pattern’, Journal of Neuro-Oncology, 115(3), pp. 505-511.
- Lee, S.J. et al. (2016) ‘Central neurocytoma: a review of clinical management and histopathologic features’, Brain Tumor Research and Treatment, 4(2), pp. 49-57.
- Schmidt, M.H., Gottfried, O.N. and von Koch, C.S. (2004) ‘Central neurocytoma: a review’, Journal of Neuro-Oncology, 66(3), pp. 377-384.
- Soliman, W.S. (2017) ‘Ventricular central neurocytoma: rate of shunting and outcome 2 years after total and subtotal excision’, Acta Neurochirurgica Supplement, 124, pp. 179-185.
- Spina, A. et al. (2024) ‘Gamma Knife radiosurgery for central neurocytoma: a quantitative systematic review and metanalysis’, Neurosurgical Review, 47(1), 64.
- National Cancer Institute (2026) Adult Central Nervous System Tumors Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/brain/hp/adult-brain-treatment-pdq (Accessed: October 2026).
Prepared by the editorial team, October 2026.